Virological efficacy and safety of telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis

Virological efficacy and safety of telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis - Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011105

Enrollment

150

Registered

2013-07-03

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C Advanced fibrosis in histology

Exclusion criteria

Exclusion criteria: Positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen Hepatic decompensation (Child B or C) Excessive active alcohol consumption

Design outcomes

Primary

Measure	Time frame
Sustained virological response	—

Secondary

Measure	Time frame
Predictors of SVR Adverse effects	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

The Kyushu University Liver Disease Study (KULDS) Group Department of General Internal Medicine, Kyushu University Hospital

eogawa@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results